div class=trans-pagebuttonPage 1button div class=trans-image amp-img class=trans-thumb alt=Page 1: hmaorgtw · the control group for seropositive participants 1-88%95% CI 154-231 in seropositive controls vs 038% 0-26—054 in seropositive vaccinees and increased by src=https:reader034fdocumentsnetreader034viewer20220424035f180af091496b79e1655a71html5thumbnails1jpg width=142 height=106 layout=responsive amp-img divdivdiv class=trans-pagebuttonPage 2button div class=trans-image amp-img class=trans-thumb alt=Page 2: hmaorgtw · the control group for seropositive participants 1-88%95% CI 154-231 in seropositive controls vs 038% 0-26—054 in seropositive vaccinees and increased by src=https:reader034fdocumentsnetreader034viewer20220424035f180af091496b79e1655a71html5thumbnails2jpg width=142 height=106 layout=responsive amp-img divdivdiv class=trans-pagebuttonPage 3button div class=trans-image amp-img class=trans-thumb alt=Page 3: hmaorgtw · the control group for seropositive participants 1-88%95% CI 154-231 in seropositive controls vs 038% 0-26—054 in seropositive vaccinees and increased by src=https:reader034fdocumentsnetreader034viewer20220424035f180af091496b79e1655a71html5thumbnails3jpg width=142 height=106 layout=responsive amp-img divdivdiv class=trans-pagebuttonPage 4button div class=trans-image amp-img class=trans-thumb alt=Page 4: hmaorgtw · the control group for seropositive participants 1-88%95% CI 154-231 in seropositive controls vs 038% 0-26—054 in seropositive vaccinees and increased by src=https:reader034fdocumentsnetreader034viewer20220424035f180af091496b79e1655a71html5thumbnails4jpg width=142 height=106 layout=responsive amp-img divdiv